A novel agent that inhibits DNA repair in cancer cells appears to be promising for safety and efficacy given along with chemotherapy using irinotecan (Camptosar), according to early-phase clinical trial results reported here.
The phase Ib trial conducted among 34 metastatic breast cancer patients found that the experimental drug iniparib yielded partial or complete responses in up to 31.8% of the patients when combined with irinotecan, Stacy Moulder, MD, MSCI, of MD Anderson Cancer Center in Houston, and colleagues found. Read more.
Monday, December 13, 2010
More Good News on PARP Inhibitors for TNBC
From the San Antonio Breast Cancer Symposium, via Medpage Today: